GEODE CAPITAL MANAGEMENT, LLC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 455 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$170,801,105
+7.4%
1,408,775
+1.5%
0.02%
+5.3%
Q2 2023$158,963,339
-8.6%
1,388,083
+10.0%
0.02%
-17.4%
Q1 2023$173,937,559
+110040.7%
1,261,971
+3.5%
0.02%
+4.5%
Q4 2022$157,923
-99.9%
1,218,732
+5.6%
0.02%
+15.8%
Q3 2022$127,596,000
+49.4%
1,154,298
+1.3%
0.02%
+46.2%
Q2 2022$85,408,000
-4.8%
1,139,383
-0.8%
0.01%
+18.2%
Q1 2022$89,734,000
-12.0%
1,148,670
+1.5%
0.01%
-8.3%
Q4 2021$101,941,000
+11.9%
1,132,056
+14.9%
0.01%0.0%
Q3 2021$91,088,000
+19.0%
984,953
+0.1%
0.01%
+9.1%
Q2 2021$76,518,000
+6.0%
984,288
+1.5%
0.01%0.0%
Q1 2021$72,190,000
-54.8%
969,763
+3.3%
0.01%
-59.3%
Q4 2020$159,879,000
+28.5%
938,883
+5.9%
0.03%
+12.5%
Q3 2020$124,396,000
-13.1%
886,581
-0.7%
0.02%
-22.6%
Q2 2020$143,091,000
+72.1%
893,126
+5.0%
0.03%
+40.9%
Q1 2020$83,158,000
-59.0%
850,806
-45.9%
0.02%
+4.8%
Q4 2019$202,864,000
+255.5%
1,573,620
+107.6%
0.02%
+61.5%
Q3 2019$57,061,000
-49.4%
758,130
+2.1%
0.01%
-51.9%
Q2 2019$112,785,000
+36.6%
742,251
+7.2%
0.03%
+28.6%
Q1 2019$82,560,000
-42.6%
692,684
-47.4%
0.02%
-4.5%
Q4 2018$143,778,000
+50.6%
1,317,506
+122.9%
0.02%
-18.5%
Q3 2018$95,476,000
+25.1%
591,152
+2.4%
0.03%
+17.4%
Q2 2018$76,342,000
+77.8%
577,565
-0.3%
0.02%
+64.3%
Q1 2018$42,927,000
+37.9%
579,392
+3.6%
0.01%
+27.3%
Q4 2017$31,128,000
+25.7%
559,456
+2.5%
0.01%
+22.2%
Q3 2017$24,758,000
+64.6%
545,825
+22.3%
0.01%
+50.0%
Q2 2017$15,043,000
+20.7%
446,269
+6.0%
0.01%
+20.0%
Q1 2017$12,462,000
+16.1%
421,047
+7.6%
0.01%0.0%
Q4 2016$10,737,000
-50.0%
391,444
+12.0%
0.01%
-54.5%
Q3 2016$21,462,000
+282.3%
349,518
+18.7%
0.01%
+266.7%
Q2 2016$5,614,000
+1.9%
294,438
+4.3%
0.00%0.0%
Q1 2016$5,510,000
-49.8%
282,292
-0.9%
0.00%
-50.0%
Q4 2015$10,986,000
+36.8%
284,781
+13.9%
0.01%
+20.0%
Q3 2015$8,030,000
+8.4%
250,104
+2.7%
0.01%
+25.0%
Q2 2015$7,411,000
+148.9%
243,573
+8.6%
0.00%
+100.0%
Q1 2015$2,977,000
-5.4%
224,189
+3.0%
0.00%0.0%
Q4 2014$3,148,000
-30.9%
217,575
+0.8%
0.00%
-33.3%
Q3 2014$4,555,000
-29.8%
215,944
-0.9%
0.00%
-25.0%
Q2 2014$6,488,000
+40.0%
217,797
+12.9%
0.00%
+33.3%
Q1 2014$4,633,000
+32.4%
192,838
+12.2%
0.00%
+50.0%
Q4 2013$3,499,000
-48.5%
171,813
+19.4%
0.00%
-60.0%
Q3 2013$6,795,000
+42.4%
143,880
+14.7%
0.01%
+25.0%
Q2 2013$4,773,000125,4380.00%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Sonic Fund II, L.P. 112,689$14,541,00014.93%
Casdin Capital, LLC 670,000$86,457,0007.95%
Logos Global Management LP 226,002$29,163,0007.19%
Avoro Capital Advisors LLC 1,760,000$227,110,0006.67%
Camber Capital Management LP 600,000$77,424,0003.94%
STANSBERRY ASSET MANAGEMENT, LLC 71,133$9,179,0003.74%
Eventide Asset Management 996,000$128,524,0003.62%
CADIAN CAPITAL MANAGEMENT, LP 550,000$70,972,0003.14%
RTW INVESTMENTS, LP 605,762$78,168,0002.95%
Consonance Capital Management LP 356,145$45,957,0002.80%
View complete list of SAREPTA THERAPEUTICS INC shareholders